Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 86

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 86
---
 the future could have rights superior to existing common stockholders, and the price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common stock in future transactions may be higher or lower than the price per Unit in this offering. If we issue shares of preferred stock your rights as a holder of our common stock or warrants may be materially adversely affected. As of the date of this prospectus, we are authorized to issue up to 1,000,000 shares of “blank check” preferred stock and 76,480 shares of Series A Preferred Stock are issued and outstanding. The designations, rights and preferences of our other preferred stock may be determined from time-to-time by our Board. Accordingly, our Board is empowered, without stockholder approval, to issue one or more series of preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of the holders of our common stock. For example, an issuance of shares of preferred stock could:

| ● | adversely                                                   
 affect the voting power of the holders of our common stock; |

| ● | make                                                       
 it more difficult for a third-party to gain control of us; |

| ● | discourage                 
 bids for our common stock; |

50

| ● | limit                                                                                       
 or eliminate any payments that the holders of our common stock could expect to receive upon 
 our liquidation; or                                                                         |

| ● | adversely                                    
 affect the market price of our common stock. |

Sales of a significant number of shares of our common stock by the Selling Stockholders and by our existing stockholders in the public markets, or the perception that such sales could occur, could depress the market price of our common stock. The Selling Stockholders can sell, under this prospectus, up to 747,200 shares of common stock. Sales of a substantial number of shares of our common stock in the public markets could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of our common stock would have on the market price of our common stock. If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline. The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Several analysts may cover our stock. If one or more of those analysts downgrade our stock or publish inaccurate or unfavorable